Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhalational anthrax and bioterrorism.

Richard Quintiliani1, Richard Quintiliani

  • 1Department of Emergency Medicine, Harvard Medical School, Somerville Hospital, Somerville, Massachusetts, USA. richard_quintiliani@hms.harvard.edu

Current Opinion in Pulmonary Medicine
|April 12, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relative bioavailability of crushed tebipenem administered through a nasogastric tube with and without enteral feeding.

The Journal of antimicrobial chemotherapy·2022
Same author

Treatment of multidrug-resistant Pseudomonas aeruginosa with ceftolozane/tazobactam in a critically ill patient receiving continuous venovenous haemodiafiltration.

International journal of antimicrobial agents·2016
Same author

Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin.

Infection control and hospital epidemiology·2015
Same author

Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit.

The Annals of pharmacotherapy·2013
Same author

Comparative pharmacokinetics, pharmacodynamics, and tolerability of ertapenem 1 gram/day administered as a rapid 5-minute infusion versus the standard 30-minute infusion in healthy adult volunteers.

Pharmacotherapy·2013
Same author

Pneumonia due to Pseudomonas aeruginosa: part II: antimicrobial resistance, pharmacodynamic concepts, and antibiotic therapy.

Chest·2011
Same journal

Nonsteroid treatment options in (pulmonary) sarcoidosis. When to consider and why?

Current opinion in pulmonary medicine·2026
Same journal

Multidisciplinary approach in cardiac sarcoidosis: to biopsy or not?

Current opinion in pulmonary medicine·2026
Same journal

Low diffusion capacity in pulmonary hypertension.

Current opinion in pulmonary medicine·2026
Same journal

Toward precision imaging in interstitial lung disease: advances in quantitative imaging and artificial intelligence.

Current opinion in pulmonary medicine·2026
Same journal

Oxygen therapy in interstitial lung disease - navigating benefit and burden.

Current opinion in pulmonary medicine·2026
Same journal

Preclinical and clinical advances in pulmonary hypertension associated with systemic sclerosis.

Current opinion in pulmonary medicine·2026
See all related articles

Inhalational anthrax, a rare disease, became a public health concern after the 2001 bioterrorism event. Prompt diagnosis and treatment are critical for survival, as delays are often fatal.

Area of Science:

  • Infectious Diseases
  • Public Health
  • Bioterrorism Preparedness

Background:

  • Inhalational anthrax, caused by Bacillus anthracis spores, was historically rare and poorly understood by most physicians.
  • The 2001 bioterrorism event highlighted the urgent need for knowledge regarding anthrax clinical manifestations, treatment, and prophylaxis.
  • Limited physician familiarity with anthrax contributed to challenges in diagnosis and management.

Purpose of the Study:

  • To address the knowledge gap regarding inhalational anthrax.
  • To review clinical manifestations, treatment, and prophylaxis based on recent bioterrorism data.
  • To identify key findings for rapid diagnosis of inhalational anthrax.

Main Methods:

  • Review of medical literature and data from the 2001 bioterrorism-related anthrax epidemic.

Related Experiment Videos

  • Emphasis on analyzing clinical manifestations to identify diagnostic clues.
  • Compilation of information on treatment and prophylaxis strategies.

    • Main Results:

    • Inhalational anthrax diagnosis requires prompt recognition of specific clinical signs.
    • Timely initiation of therapy significantly improves patient outcomes.
    • Delayed treatment of inhalational anthrax is associated with high mortality rates.

    Conclusions:

    • Rapid diagnosis of inhalational anthrax is paramount for effective patient management.
    • Physicians need enhanced awareness of anthrax clinical presentations.
    • Preparedness for bioterrorism events involving Bacillus anthracis is essential for public health.